INTRODUCTION
Choline, an essential dietary component for mammals, may have two metabolic fates. It can be phosphorylated to phosphocholine and committed to the biosynthetic pathway leading to phosphatidylcholine. Alternatively, it can enter the mitochondria and be oxidatively degraded to glycine (Scheme 1). At physiological concentrations, choline enters the mitochondria via a specific transporter [1] which has been shown to be the major site for control ofcholine oxidation in isolated rat liver mitochondria. The first enzyme of the choline oxidation pathway, choline dehydrogenase, an oligomeric protein complex of the inner mitochondrial membrane, has been shown in both rats and humans to be expressed mainly in liver and kidney [2] . Choline dehydrogenase is a flavoenzyme which contains FAD as prosthetic group; betaine aldehyde formed in the choline dehydrogenase reaction is converted into betaine by the NAD+-linked betaine aldehyde dehydrogenase, an enzyme of the mitochondrial matrix [3] . In the kidney, betaine plays an important role as an organic osmolyte [4] . In the mammalian liver, betaine is an essential methyl-group donor for the synthesis of methionine from homocysteine, a reaction catalysed by betainehomocysteine methyltransferase. This enzyme was recently shown to be located in the cytoplasm of liver and kidney cells of man and pig, but only in the liver of the rat [5] . Betaine thus has to efflux from the mitochondria into the cytoplasm of the liver cell in order to function as a methyl donor in the synthesis of methionine. Porter et al. [6] showed recently that efflux of betaine from the mitochondrion is a simple diffusion process which is proportional to the intramitochondrial concentration of the substance. Betaine is transformed into dimethylglycine in the betaine-homocysteine methyltransferase reaction. The last two reactions in the oxidative pathway from choline to glycine, catalysed by dimethylglycine dehydrogenase (Me2GlyDH) and sarcosine dehydrogenase, are located in the mitochondrial matrix tectable in liver macrophages (Kupffer cells) and only a very faint one in fat-storing cells (Ito cells). Western blots confirmed at the protein level the predominant expression of the enzyme in liver and kidney, but Me2GlyDH protein was also present in the protein extract of lung, heart, spleen and brain. Immunohistochemical staining of liver slices with Me2GlyDH-specific antiserum revealed that expression ofthis enzyme is evenly distributed throughout the liver tissue. In the kidney, expression of the enzyme was located in the proximal tubule cells. Our results demonstrate that, contrary to the previously assumed liverrestricted expression, this enzyme is specifically expressed predominantly in the liver and kidney, but, in addition, it is detectable in many other tissues of the rat. [7, 8] . Thus dimethylglycine must be transported back across the inner mitochondrial membrane into the matrix. This may be a diffusion-dependent process, as it has been shown that the diffusion rates of betaine, dimethylglycine, sarcosine and glycine across the mitochondrial membrane increase with decreasing degree of N-methylation of these compounds [6] . Me2GlyDH and sarcosine dehydrogenase have been identified as the folatebinding proteins of the hepatocyte mitochondrial matrix and were thought to be present in rats exclusively in the liver [7] [8] [9] .
We have previously described the characterization of a Me2GlyDH cDNA clone [10] . With the aid of oligonucleotides derived from this cDNA and Me2GlyDH-specific antiserum, we investigated the expression of this enzyme at the mRNA and protein level in various tissues, liver cells and developmental stages of the rat. Contrary to previous reports, our results demonstrate that Me2GlyDH is expressed at increased levels in both liver and kidney, and that detectable levels of expression can be demonstrated at the RNA and protein level in heart, brain, lung and spleen also. Within the liver, besides high levels of expression in hepatocytes, endothelial cells also expressed the enzyme, but liver macrophages (Kupffer cells) and fat-storing cells (Ito cells) showed no or a very low level of expression respectively. Immunohistochemical analysis of liver slices revealed an even expression of the enzyme throughout the hepatocyte population. In the kidney, expression of Me2GlyDH was located to the cells of the proximal tubule. Plasmid DNA was propagated in and isolated from Escherichia coli JM109 [11] .
EXPERIMENTAL

Source of biological tissue and cells
Liver, spleen, lung, heart, kidney and brain tissue samples were taken from 3-month-old female Wistar rats. For monitoring Me2GlyDH expression during ontogeny, rat embryos were taken 14 days post coitum. In addition, livers and kidneys were taken from 7-day-and 18-day-old rats.
The cell-type-specific expression of Me2GlyDH within the liver was performed on primary cultures of hepatocytes, fat-storing cells (Ito cells), liver macrophages (Kupffer cells) and sinusoidal endothelial cells. Primary cultures ofhepatocytes were established as described in [12] ; Ito cells were prepared and cultured as described in [13] ; Kupffer cells and sinusoidal endothelial cells were prepared as described by Brouwer et al. [14] as modified by Eyhorn et al. [15] . After 48 h in culture, the cells were counted, rinsed three times with PBS and frozen in liquid nitrogen. They were then used for total RNA extraction.
RNA extraction, Northern-blot hybridization and DNA PCR Total RNA was extracted from rat tissue and cell cultures as described in [16] , including a DNAase step. The RNA preparations were analysed on 1 % formaldehyde-agarose gels, and the intactness of the RNA was judged by the presence in equal amounts of the 18 S and 28 S ribosomal RNA bands on the ethidium bromide-stained gel (results not shown). Northern primer-labelled rat fl-actin cDNA and rat Me2GlyDH cDNAderived probes were performed by standard protocols [11] .
First-strand cDNA synthesis from total RNA was achieved with a commercial kit purchased from Pharmacia (Freiburg, Germany). Amplification of the synthesized cDNA was performed with Taq DNA polymerase (Amersham, Braunschweig, Germany) and the following oligonucleotides: a 5' and 3' ,l-actin cDNA-specific oligonucleotide (5'-TCTACAATGAGCTGCGTGTGG-3' and 5'-CCATAGG-CAGAATGTCAGGA-3' respectively) and a 5' and 3' Me2GlyDH cDNA-specific oligonucleotide (5'-GAAGGACA-GGAAAGCCCACC-3' and 5'-CCATAGGCAGAATGTCA-GGA-3' respectively). The reaction conditions for the PCR were as described by the supplier of the first-strand cDNAsynthesis kit (Pharmacia). As internal standard either pSPTxcDDHldeltaSmaI or RNA transcribed from this plasmid in vitro was added to the samples as described in the legends to the Figures. Taq DNA polymerase was added to the incubation mixtures preheated to 93 'C. Annealing of the oligonucleotides was at 63 'C for 15 s, followed by DNA synthesis at 72 'C for 2 min and melting of the hybrids at 93 'C. The PCR cycle was repeated 35 times. The PCR products were analysed by gel electrophoresis on 1 % agarose gels, stained with ethidium bromide, visualized under u.v. light and photographed using a Polaroid camera.
Immunoprecipitation of Me2GIyDH and Western blots
For the analysis of Me2GlyDH expression at the protein level, liver, kidney, spleen, brain, heart and lung were taken from 3-month-old female Wistar rats. The tissues were immediately frozen in liquid nitrogen, crushed to a powder and homogenized in a glass Potter-Elvehjem homogenizer in 50 mM Tris/HCl, pH 7.4, buffer containing 100 mM NaCl, 1 
RESULTS
Northern-blot analysis of total rat liver RNA and immunoprecipitatlon of Me2GIyDH from rat liver extract Northern blots of rat total liver RNA hybridized to a 32P-labelled Me2GlyDH cDNA probe gave no hybridization signal ( Figure  la, lane 2) . When the same Northern blot was hybridized with an actin cDNA-specific probe, the expected signal was readily detectable (Figure la, lane 1) . Immunoprecipitation of liver cell extract with Me2GlyDH-specific antiserum revealed on Coomassie Brilliant Blue-stained polyacrylamide gels the presence of the Me2GlyDH protein band (Figure lb) . From the intensity of the stained Me2GlyDH on the polyacrylamide gel, we assume that the enzyme is not a protein of low abundance in the liver. Therefore it seems that transcription of the Me2GlyDH gene is low or the transcribed mRNA instable. .. Hybridization of actin-specific and Me2GIyDH-specitic probes to Northern blots of total rat liver RNA and immunoprecipitation of rat liver extract with Me2GIyDH-specific antiserum was performed as described in the Experimental section. Amplffication of Me2GlyDH-specfflc RNA from various rat tissues by reverse transcription and PCR Because of the low level of Me2GlyDH mRNA, we analysed expression of the Me2GlyDH gene in different rat tissues using the PCR technique. Total rat RNA from liver, spleen, brain, kidney, lung and heart was first reverse-transcribed into cDNA and then amplified with the oligonucleotide pairs described in the Experimental section. The primers selected from the Me2GlyDH cDNA sequence gave, on amplification, a 1042 bp DNA fragment. As a positive control, two oligonucleotide primers derived from the ubiquitously expressed fl-actin gene were employed.
Amplification of the ,-actin cDNA with this primer pair resulted in a 744 bp DNA fragment. Control reactions with RNA samples not transcribed into cDNA gave no amplification product. For a semiquantitative evaluation of the reaction products, 1 pg of pSPT19xcDDHldeltaSmaI DNA was added to the reversetranscribed samples before amplification with the Me2GlyDH-specific primers. From this internally deleted cDNA construct, a 782 bp DNA product was amplified with the Me2GlyDH primers. As a control for the reverse transcription reaction, 25 pg of in vitro transcribed pSPTxcDDHldeltaSmaI RNA was added to the RNA samples before reverse transcription in alternative series of reverse transcription-PCR. Figure 2 illustrates the tissue-specific distribution of Me2GlyDH expression in the rat. The main tissues that expressed the enzyme were liver and kidney. The DNA fragment amplified from the reverse-transcribed RNA with the Me2GlyDH-specific primer pair migrated identically with the DNA fragment amplified with the same oligonucleotides from authentic Me2GlyDH cDNA and exhibited the same restriction enzyme pattern (not shown). In addition to liver and kidney, detectable levels of Me2GlyDH expression were present in all the organs analysed except spleen (Figure 2a) . A comparison of the expression of the enzyme in different tissues according to the internal RNA standard showed that, after kidney and liver, lung exhibited the highest level of expression, followed by heart and brain (Figure 2b ). The specificity of Me2GlyDH expression within various liver cell types is presented in Figure 3 . As expected hepatocytes showed the highest level of expression (Figure 3a) . Quantification according to the internal RNA standard revealed that endothelial cells also expressed the enzyme mRNA to an appreciably high level (Figure 3b) . No Me2GlyDH cDNA-specific amplification product was detectable in RNA from liver macrophages (Kupffer cells) and only a very faint amplification signal in RNA from fat-storing cells (Ito cells).
The basic importance of this enzyme of choline catabolism in rat was demonstrated by the fact that its mRNA was readily detectable in total RNA samples extracted from 14-day whole embryos (Figure 4) . As a control the amplification product obtained from a sample prepared from total liver RNA of 18- day-old rats is shown (Figure 4a, lane 2) . A demonstrated that, at this stage after birth, there was no difference among the tissues in the levels of expression of the enzyme mRNA (Figure 4b ). [18] , which corresponds to the tissue-specific expression of choline dehydrogenase, betaine aldehyde dehydrogenase and betaine-homocysteine methyltransferase as described for man and pig [5] . Our results indicate that, in contrast with previous reports [7] [8] [9] , Me2GlyDH is expressed in the kidney in accordance with the tissue distribution of the other enzymes of choline catabolism.
Analysis of individual liver cell types for expression of Me2GlyDH at the cDNA level indicated that epithelial cells have this ability. Thus expression of this enzyme is not only liver-and kidney-specific, but also characteristic of liver endothelial cells. It was not possible to analyse the expression of Me2GlyDH in epithelial cells of other origin. It cannot, however, be excluded that the low level expression found in lung, heart, brain and spleen is due to the expression of Me2GlyDH in the endothelial components of these tissues.
In the liver, expression of enzyme is evenly distributed among hepatocytes. In the kidney, however, there is a correlation between the distribution of the expression of Me2GlyDH and the distribution of betaine. Betaine is one of several organic osmolytes and is synthesized from choline by proximal tubule and renal medullary cells. After salt loading, rats accumulate large amounts of betaine in their renal medullas (for a review see [4] ). The correlation in the distribution of betaine and Me2GlyDH within the kidney may indicate that at least some of the betaine accumulated in the kidney can be further oxidized by this tissue to glycine via Me2GlyDH and sarcosine dehydrogenase.
Me2GlyDH was found to be expressed in 14-day rat embryos. This underlines the basic importance of this enzyme and the choline-catabolic pathway in general. It may be assumed that the other enzymes of the pathway are also expressed early during embryogenesis. Our results show that Me2GlyDH exhibits an interesting pattern of developmentally and tissue-specific regulated expression.
